CAMBRIDGE, Mass., Feb. 6, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced that ...
In participants who received PrimeC from the start of the 18-month study compared to those initially on placebo before transitioning to PrimeC, disease progression was slowed by 33% (p=0.007), ...
CAMBRIDGE, Mass., July 9, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe ...
The PARADIGM Trial is a prospective randomized controlled trial (RCT) which will evaluate the safety and effectiveness of the DurAVR ® THV compared to commercially available transcatheter aortic valve ...
“Our team has been convinced of the need for a paradigm shift in clinical research for years, especially with a focus on improving equitable access. Our name reflects the change that we want to create ...
Bristol Myers Squibb is putting Paradigm’s plans to rebuild the clinical trial system to the test, teaming up with the startup to design studies that can activate community health provider ...
Axsome Therapeutics, Inc. (NASDAQ:AXSM) on Tuesday released results of the PARADIGM Phase 3 proof-of-concept trial of solriamfetol in major depressive disorder (MDD) with and without severe excessive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback